VRDN — Viridian Therapeutics, Inc.

Summary of Viridian Therapeutics Q1 2024 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: Viridian ended Q1 2024 with $613 million in cash, cash equivalents, and short-term investments, providing a runway into the second half of 2026.

2. Strategic Updates and Business Highlights

• Pipeline Progress:

  • 001 IV Program: Completed enrollment for the Phase III THRIVE trial with 113 patients (target was 90) and expects top-line results in September 2024. A second Phase III trial, THRIVE 2, is ongoing with expected data by year-end.
  • 003 Subcutaneous Program: Positive Type C meeting with the FDA; pivotal trials expected to start mid-year 2024. The program aims to offer a best-in-class subcutaneous therapy with an extended half-life.
  • FcRn Portfolio: Plans to file an IND for 006 by year-end 2024 and share nonhuman primate data for 008 in the second half of 2024.

• Market Opportunity: The thyroid eye disease (TED) market is significant, with an estimated 190,000 patients in the U.S. alone. Current treatment options are limited, presenting an opportunity for Viridian's differentiated therapies.

3. Forward Guidance and Outlook

• BLA Submission: Anticipated for the 001 program in the second half of 2025, contingent on the completion of THRIVE 2 and the safety database from the STRIVE study.
• Clinical Trials: Continued focus on executing clinical trials with strong patient enrollment and interest in TED therapies.

4. Bad News, Challenges, or Points of Concern

• Competition: The presence of competing therapies, such as TEPEZZA, raises concerns about market share and patient enrollment dynamics.
• Safety Profile: Questions regarding the safety profile, particularly related to hearing impairment, were raised. The company is implementing measures to monitor and report adverse events similar to those in TEPEZZA trials.
• Market Dynamics: TEPEZZA sales have shown slight declines, indicating potential market saturation or challenges in patient acquisition, which could impact Viridian's growth.

5. Notable Q&A Insights

• Efficacy Expectations: Management indicated that achieving efficacy results similar to TEPEZZA would be considered successful for the THRIVE trial.
• Safety Monitoring: The company is employing rigorous safety monitoring protocols, including audiometry assessments, to address concerns about hearing loss in TED patients.
• Regulatory Pathway for 003: The pivotal trials for the 003 program will not leverage the safety database from STRIVE, as it is considered a different molecular entity.
• Enrollment Strategies: Strong patient demand was noted, with successful enrollment exceeding expectations, suggesting robust interest in Viridian's TED therapies.

Overall, Viridian Therapeutics is making significant strides in its clinical programs while navigating competitive pressures and safety concerns in the evolving TED treatment landscape.